MedTrace Logo

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

NCT06077656 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2026-03-17

Study results available
· View outcomes & findings →

Summary

Phase 2 trial to evaluate safety, tolerability, and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25)

Conditions

  • Pneumococcal Vaccines

Interventions

BIOLOGICAL

IVT PCV-25 Formulation A

25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and low dose adjuvant

BIOLOGICAL

IVT PCV-25 Formulation B

25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and high dose adjuvant

BIOLOGICAL

IVT PCV-25 Formulation C

25 valent pneumococcal conjugate vaccine containing high dose polysaccharide and high dose adjuvant

BIOLOGICAL

PCV 20

20 valent pneumococcal conjugate vaccine

Sponsors & Collaborators

  • Canadian Center for Vaccinology

    collaborator OTHER

  • Vaccine Evaluation Center, Canada

    collaborator OTHER

  • PATH

    collaborator OTHER

  • Inventprise Inc.

    lead INDUSTRY

Principal Investigators

  • Sybil Tasker, MD, MPH, FIDSA · Inventprise Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-25
Primary Completion
2024-05-24
Completion
2024-05-24

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06077656 on ClinicalTrials.gov